Immunocore, an Oxford, UK-based biotechnology company, which is developing drugs to treat cancer and viral disease, has appointed Eva-Lotta Allan to the Board as Chief Business Officer. This is a new position, which has been created to strengthen the company’s management team as Immunocore continues to expand its operations.
Immunocore has created a T cell receptor technology and is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and US.
Allan brings more than 20 years of business development experience from the biotechnology and life science industry to Immunocore and joins from Ablynx, where she has been Chief Business Officer since 2006.
Prior to Ablynx, Allan was Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals.
